Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Change in Receivables (2020 - 2026)

Cytek Biosciences filings provide 6 years of Change in Receivables readings, the most recent being $6.1 million for Q4 2025.

  • On a quarterly basis, Change in Receivables fell 34.12% to $6.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$368000.0, a 106.78% decrease, with the full-year FY2025 number at -$368000.0, down 106.78% from a year prior.
  • Change in Receivables hit $6.1 million in Q4 2025 for Cytek Biosciences, up from $587000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $9.3 million in Q4 2024 to a low of -$6.4 million in Q1 2025.
  • Median Change in Receivables over the past 5 years was $2.4 million (2022), compared with a mean of $2.2 million.
  • Biggest five-year swings in Change in Receivables: plummeted 683.33% in 2023 and later soared 3647.15% in 2024.
  • Cytek Biosciences' Change in Receivables stood at $720000.0 in 2021, then soared by 1006.11% to $8.0 million in 2022, then tumbled by 103.3% to -$263000.0 in 2023, then soared by 3647.15% to $9.3 million in 2024, then tumbled by 34.12% to $6.1 million in 2025.
  • The last three reported values for Change in Receivables were $6.1 million (Q4 2025), $587000.0 (Q3 2025), and -$652000.0 (Q2 2025) per Business Quant data.